ARTICLE | Company News
Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11 on Jan. 19, before the deal was announced.
The deal gives Sanofi marketed drugs Eloctate efmoroctocog alfa for hemophilia A and Alprolix eftrenonacog alfa for hemophilia B. Combined sales of the drugs were $780.7 million in the first nine months of 2017. Both long-acting clotting factor replacements previously belonged to Biogen Inc. (NASDAQ:BIIB), which spun out its hemophilia assets to create Bioverativ in February 2017 (see BioCentury, Feb. 10, 2017)...